These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33586606)

  • 21. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 22. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Al-Samkari H; Kolb-Sielecki J; Safina SZ; Xue X; Jamieson BD
    Lancet Haematol; 2022 Mar; 9(3):e179-e189. PubMed ID: 35240074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment.
    Lebowa W; Zdziarska J; Sacha T
    Blood Coagul Fibrinolysis; 2023 Jul; 34(5):327-332. PubMed ID: 37395226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Mei H; Liu X; Li Y; Zhou H; Feng Y; Gao G; Cheng P; Huang R; Yang L; Hu J; Hou M; Yao Y; Liu L; Wang Y; Wu D; Zhang L; Zheng C; Shen X; Hu Q; Liu J; Jin J; Luo J; Zeng Y; Gao S; Zhang X; Zhou X; Shi Q; Xia R; Xie X; Jiang Z; Gao L; Bai Y; Li Y; Xiong J; Li R; Zou J; Niu T; Yang R; Hu Y
    J Hematol Oncol; 2021 Feb; 14(1):37. PubMed ID: 33632264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
    Maitland HS
    Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avatrombopag.
    Bussel JB
    Br J Haematol; 2018 Nov; 183(3):342-343. PubMed ID: 30351482
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.
    Nomoto M; Pastino G; Rege B; Aluri J; Ferry J; Han D
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):188-195. PubMed ID: 28339166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
    Gao Y; Liu Q; Shen Y; Li Y; Shao K; Ye B; Shen Y; Zhou Y; Wu D
    Platelets; 2022 Oct; 33(7):1024-1030. PubMed ID: 35040375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avatrombopag: First Global Approval.
    Shirley M
    Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
    Cheloff AZ; Al-Samkari H
    J Blood Med; 2019; 10():313-321. PubMed ID: 31565009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB; Keating GM; Garnock-Jones KP
    Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.